Drug Profile

AVG 002

Alternative Names: AVG-002

Latest Information Update: 11 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AlveoGene
Class Gene therapies
Mechanism of Action Gene transference; SFTPB protein replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Congenital deficiency of pulmonary surfactant protein B
New Molecular Entity No

Highest Development Phases

Preclinical Congenital deficiency of pulmonary surfactant protein B

Most Recent Events

03 Dec 2024 AlveoGene plans a clinical trial in Congenital deficiency of pulmonary surfactant protein B (Inhalation)
03 Dec 2024 AVG 002 receives Orphan Drug status for Congenital deficiency of pulmonary surfactant protein B in USA
15 Nov 2024 Preclinical trials in Congenital deficiency of pulmonary surfactant protein B in United Kingdom (Inhalation)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com